The PCOS diagnostic market is estimated to be valued at US$ 710.0 Mn or Million in 2023 and is expected to exhibit a CAGR of 5.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

PCOS or Polycystic Ovary Syndrome is a fairly common health condition among women of reproductive age that can cause irregular menstrual periods, excess hair growth, acne, and obesity. PCOS poses health challenges such as cardiovascular disease, diabetes, and other metabolic conditions. Regular screening and early diagnosis of PCOS plays a key role in timely intervention and treatment.

Market Overview:
PCOS diagnostic includes various laboratory tests and imaging procedures used to evaluate and diagnose PCOS in women. Common diagnostic tests involve hormone level tests such as Luteinizing hormone (LH), follicle-stimulating hormone (FSH) and testosterone. Ultrasound scans help visualize cysts on ovaries. Increased demand for minimally invasive diagnostic procedures and point-of-care tests is driving the market growth.

Market key trends:
One of the key trends witnessed in the PCOS diagnostic market is the growing adoption of infertility screening tests. As infertility is a major complication associated with PCOS, it is crucial to screen women with PCOS for fertility issues in order to plan further treatments. Biomarker-based non-invasive prenatal testing is gaining popularity for early and accurate PCOS detection. Several market players are focusing on developing advanced screening tests incorporating the use of proteomics and metabolomics for comprehensive PCOS diagnostics. Such advanced tests provide better fertility counseling while removing the need for invasive procedures. This trend is expected to significantly drive the future growth of the PCOS diagnostic market.

Porter’s Analysis
Threat of new entrants: The presence of well-established diagnostic players and high capital investments required to develop diagnostics pose a barrier for new entrants.

Bargaining power of buyers: The fragmented nature of buyers given the wide patient pool for PCOS diagnosis limits the buyers' bargaining power.

Bargaining power of suppliers: The availability of alternative suppliers of raw materials and reagents reduces suppliers' bargaining power.

Threat of new substitutes: No major threat of new substitutes exists.

Competitive rivalry: High due to presence of major diagnostic players.

SWOT Analysis
Strength: Non-invasive diagnostic techniques such as ultrasound provide convenience. Wide prevalence of PCOS condition globally increases market potential.
Weakness: Lack of disease awareness in developing regions. High costs associated with diagnostic tests limits wide adoption.
Opportunity: Growing healthcare expenditure increases investment in female health conditions. Development of affordable point-of-care tests expands access.
Threats: Social stigma associated with female health conditions. Stringent regulatory approvals delay market entry.

Key Takeaways

The global PCOS diagnostic market is expected to witness high growth, exhibiting CAGR of 5.3% over the forecast period, due to increasing disease prevalence globally. North America dominates the market currently due to high healthcare spending and diagnostic reimbursements.

Regional analysis Asia Pacific is expected to be the fastest growing market due to rising medical tourism, increasing healthcare expenditure, and growing focus on women's health issues.

Key players operating in the PCOS diagnostic market are AbbVie, Novartis AG, Bausch Health Companies Inc., Galapagos NV, EyePoint Pharmaceuticals, Inc., Clearside Biomedical, Tarsier Pharma Ltd, Santen Pharmaceutical Co., Ltd., Bausch Lomb Incorporated, Sanofi, Regeneron Pharmaceuticals, and Inc., Alimera Sciences